BLAINJECTIONINJECTABLE
Approved
Feb 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
2/8 — Basic
SIMLANDI (adalimumab-ryvk) by Alvotech is tnf-alpha and block its interaction with the p55 and p75 cell surface tnf receptors. First approved in 2024.
Drug data last refreshed 43m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SIMLANDI (adalimumab-ryvk) is a biosimilar TNF-alpha inhibitor approved in February 2024 for inflammatory conditions including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, and psoriasis. It works by binding TNF-alpha and blocking its interaction with cell surface receptors, modulating inflammatory and immune responses. The drug is administered via injection and represents a lower-cost alternative to reference adalimumab products in a competitive TNF-inhibitor market.
Growth
Early-stage biosimilar launch phase with active commercial build-out; expect expansion in field sales, market access, and revenue analytics roles as market penetration accelerates.
Mechanism of Action
TNF-alpha and block its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab products also lyse surface TNF expressing cells in vitro in the presence of complement. Adalimumab products do not bind or inactivate lymphotoxin (TNF-beta). TNF is a naturally occurring cytokine that is…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
SIMLANDI roles span manufacturing scale-up (R&D, Manufacturing), market access (Revenue Analysts, Financial Reporting), and regulatory compliance (Artwork Coordination). This biosimilar launch creates opportunities in operational excellence and commercial analytics rather than clinical innovation. Career growth depends on driving adoption metrics, payer negotiations, and operational efficiency in a price-sensitive segment.
Worked on SIMLANDI at Alvotech? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.